Patent · US Active

Compositions and methods of use of EPB1, and ErbB3 binding protein

US7838495B2 · kind B2 · utility

0Cited by

2References

42Claims

0Family size

Assignee

UNIVERSITY OF MARYLAND, BALTIMORE · US

Inventors

Yuexing Zhang · Naperville, US
Anne Hamburger · Baltimore, US

Key dates

Filing date	Apr 25, 2008
Grant date	Nov 23, 2010
Priority date	—
Expiry date	Apr 25, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Inhibition of the proliferation of hormone refractory prostate cancer cells is achieved by administering EPB1, an ErbB3 binding protein, in combination with another anti-proliferation therapy such as administration of antiandrogens, other anticancer agents, radiation therapy, or surgery. Administration of EPB1 reverses the phenotype of hormone-resistant prostate cancer cells to hormone-sensitive prostate cancer cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.